Form 8-K · Current report
Boston Scientific 8-K, filed Oct 7, 2026
- Filed
- CIK
- 0000885725
- Accession no.
- 0000885725-26-000064
Summary
Boston Scientific announced that Joseph M. Fitzgerald will become executive vice president and chief operating officer on Jan. 1, 2027, and that the company will establish three reportable segments—Interventional Therapies, Rhythm Solutions and MedSurg—on the same date. The company also said Emily Woodworth will become senior vice president, Global Finance Controller and Finance Transformation, and Mark Bickel will become senior vice president, Global Accounting Controller and chief accounting officer, both effective March 1, 2027.
Key points
- Joseph M. Fitzgerald, currently executive vice president and group president, Cardiovascular, will become COO on Jan. 1, 2027, overseeing global operations, business units and regions.
- Boston Scientific will create three reportable segments—Interventional Therapies, Rhythm Solutions and MedSurg—effective Jan. 1, 2027; Lance Bates, Nick Spadea-Anello and Stephen Morse will lead them and report to Fitzgerald.
- Emily Woodworth will become senior vice president, Global Finance Controller and Finance Transformation effective March 1, 2027, and Mark Bickel will become senior vice president, Global Accounting Controller and chief accounting officer on the same date.
- Fitzgerald's 2027 compensation includes a $1,050,000 base salary, a 110% bonus target and a $7,000,000 equity award; Woodworth's transition was not due to any disagreement with the company.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
- 8.01Other Events
- 9.01Financial Statements and Exhibits
From the filing
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Chief Operating Officer On October 7, 2026, Boston Scientific Corporation (the “Company”) announced that Joe Fitzgerald, who currently serves as Executive Vice President and Group President, Cardiovascular, has been promoted to Executive Vice President and Chief Operating Officer of the Company, effective as of January 1, 2027. Mr. Fitzgerald, age 63, joined the Company in 1990, and has held a variety of management positions in the Company’s Cardiovascular business. In his current position, which he has held since May 2022, Mr. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.